Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Genmab ( (GMAB) ).
On November 26, 2025, Genmab A/S announced updates to its Articles of Association, which include authorizations for the Board of Directors to increase the company’s share capital and issue warrants and convertible debt instruments. These changes are aimed at providing financial flexibility and supporting the company’s growth strategy, potentially impacting shareholder value and market positioning.
The most recent analyst rating on (GMAB) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.
Genmab’s strong financial performance and positive earnings call sentiment are the primary drivers of its score. The company’s strategic initiatives and solid valuation further support its potential, despite some technical indicators suggesting caution.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab A/S is a Danish biotechnology company engaged in medical research, production, and sale of related products. The company focuses on developing innovative antibody therapeutics for the treatment of cancer and other serious diseases.
Average Trading Volume: 2,115,301
Technical Sentiment Signal: Buy
Current Market Cap: $19.07B
Learn more about GMAB stock on TipRanks’ Stock Analysis page.